Inhibition of FOXQ1 induces apoptosis and suppresses proliferation in prostate cancer cells by controlling BCL11A/MDM2 expression

XIANG ZHANG1,2, LIUJUAN WANG3, YINGMEI WANG4, SHENJIA SHI5, HUAYU ZHU6, FENGJIN XIAO1, JING YANG1, ANGANG YANG2 and XIAOKE HAO1

1Department of Clinical Laboratory Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032; 2Department of Immunology, Basic Medical College, Fourth Military Medical University, Xi'an, Shaanxi 710032; 3Department of Oncology, The First Affiliated Hospital, College of Medicine, Xi'an Jiaotong University, Xi'an, Shaanxi 710032; 4Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032; 5Department of Aristogenesis, No. 202 Hospital of PLA, Shenyang, Liaoning 110000; 6Department of Burns and Cutaneous Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China

Received February 3, 2016; Accepted March 15, 2016

DOI: 10.3892/or.2016.5018

Abstract. Forkhead box Q1 (FOXQ1) has been recognized as an oncogene that is overexpressed in different cancers, and several studies have shown that FOXQ1 is related to apoptosis and proliferation in many cancer types. However, the role and the molecular mechanism of FOXQ1 in prostate cancer remains unclear. In this study, we aimed to explore the role of FOXQ1 in regulating cell apoptosis, proliferation and invasion in prostate cancer and the underlying mechanism. We found that FOXQ1 was highly expressed in the prostate cancer tissues and cell lines. In our FOXQ1 loss-of-function experiments, the data indicate that the expression of BCL11A and MDM2 was significantly downregulated, prostate cancer cell proliferation and invasion were markedly suppressed, and apoptosis was significantly induced. Moreover, overexpression of BCL11A obviously reversed the effect of FOXQ1 inhibition on apoptosis, proliferation and invasion of prostate cancer cells. In addition, BCL11A overexpression also abrogated the inhibitory effect of FOXQ1 suppression on MDM2 expression. Taken together, our study suggests that FOXQ1 regulates prostate cancer cell proliferation and apoptosis by controlling BCL11A/MDM2 expression and indicates that FOXQ1 may serve as a potential therapeutic target for prostate cancer.

Introduction

Prostate cancer is the most common male genitourinary system malignancy, and causes major public health problems worldwide (1,2). The incidence of prostate cancer in older men is rapidly increasing every year (3). Cancer often compromises adjacent tissues and organs during the development of the disease and can result in a wide range of bone metastases, seriously affecting the survival and quality of life of patients. Thus far, the underlying molecular mechanism of prostate cancer remains unclear. To this end, it is necessary to investigate the biological mechanism driving prostate cancer to provide novel insight into the prevention and therapeutic management of this disease.

Forkhead box Q1 (FOXQ1) is a transcription factor that exerts its biological effects by controlling gene transcription activity (4–6). FOXQ1 encodes a forkhead box (FOX) family related protein (6–8). The FOX family is involved in the regulation of various biological activities, such as development (7,9), metabolism (10), cancer (11), and aging (12). In recent years, the role of FOXQ1 as a proto-oncogene has gradually been recognized, and it is found in colon cancer (7), ovarian cancer (13), breast cancer (7,14), nasopharyngeal carcinoma (15), glioma (16), non-small cell lung cancer (NSCLC) (17) and other tumors. Moreover, FOXQ1 plays a role in proliferation (18), drug resistance (19), epithelial-mesenchymal transition (EMT) (19), angiogenesis (17) and metastasis (20) in cancer. It has been reported that FOXQ1 is upregulated in
coli, colorectal cancer, inhibiting apoptosis and accelerating tumor growth (21). Moreover, FOXQ1 has a significant function in tumor growth in bladder cancer (22). FOXQ1 promotes the invasive ability of laryngeal carcinoma (23) and enhances the metastasis of hepatocellular carcinoma and non-small cell lung cancer by regulating EMT (4,17). However, the role of FOXQ1 in prostate cancer remains poorly understood.

BCL (B cell lymphoma/leukemia) 11A is a member of the BCL family, and is a transcription factor that negatively regulates fetal hemoglobin generation (24). BCL11A is expressed in the bone marrow, spleen, B and T cells, monocytes and megakaryocytes (25). Additionally, BCL11A is related to the development of B cell malignancies, in which it is expressed at high levels (26). BCL11A is upregulated by FOXQ1 overexpression in colorectal cancer and acute myeloid leukemia (21,27).

Studies have indicated that BCL11A regulates the expression of murine double minute 2 (MDM2) (25,28). MDM2 encodes for a protein that acts as a major regulator of the tumor-suppressor gene p53, and is involved in the regulation of cell growth, apoptosis and the cell cycle (29,30). MDM2 is overexpressed in human gastric cancer, bladder cancer and sarcoma, and expressed at lower levels in the corresponding normal tissues, suggesting that MDM2 plays a role in the course of cancer development (31-33). It has been indicated that MDM2 inhibition induces apoptosis in hepatoma and constrains the proliferation and invasion of these cells (34). Moreover, studies have indicated that MDM2 is a potential target for prostate cancer therapy, as downregulation of MDM2 suppresses prostate cancer cell proliferation and metastasis and promotes apoptosis (35).

In this study, we aimed to investigate the role of FOXQ1 in regulating prostate cancer cell proliferation and apoptosis and its potential relationship with BCL11A and MDM2. We found that FOXQ1 is overexpressed in prostate tissues and cancer cell lines and the inhibition of FOXQ1 induces cells apoptosis and suppresses the proliferation and invasion of prostate cancer cells. Moreover, the data demonstrate that FOXQ1 may play a role in regulating MDM2 by controlling BCL11A in prostate cancer. Our study suggests that FOXQ1 plays an important role in prostate cancer and provided a novel insight into preventing and treating prostate cancer through targeting DOXQ1.

Materials and methods

Cell lines. Human prostate cancer cell lines (PC-3, DU-145 and LNCaP) were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). These cell lines were cultured in RPMI-1640 with 10% fetal bovine serum (FBS) (both from Hyclone, Salt Lake City, UT, USA) and 1% penicillin/streptomycin (Gibco, Rockville, MD, USA). Additionally, the human non-neoplastic prostatic epithelial RWPE-1 obtained from the American Type Culture Collection (ATCC: Rockwell, MD, USA) were maintained in keratinocyte serum-free medium (Gibco) containing 50 µg/ml of bovine pituitary extract, 0.5% penicillin/streptomycin mix, and 5 ng/ml epidermal growth factor. The cell lines were cultured in a humidified atmosphere containing 5% CO₂ at 37°C.

Tissue specimens. Tumor tissues and matched adjacent normal tissues were obtained from Fourth Military Medical University and tissues were cryopreserved immediately following laparoscopic radical prostatectomy. The set of prostate tissues included 10 tumor tissues and 10 matched adjacent normal tissues. The study was approved by the hospital ethics board.

Real-time quantitative polymerase chain reaction (RT-qPCR) assay. Total RNA was extracted from cell lines using TRIzol (Thermo Fisher Scientific, Waltham, MA, USA). The method of total RNA extraction from tissues was performed according to the literature (36). Subsequently, the total RNA was synthesized into cDNA using the RevertAid First Strand cDNA Synthesis kit (Thermo Fisher Scientific) as per the protocol. All of the RT-qPCR reactions used 20 µl, with 10 µl of SYBR Green PCR Master Mix (Applied Biosystems, Carlsbad, CA, USA) and primers as follows: FOXQ1 forward, 5'-ATTTCCTTGCTATTGACCATGC-3’ and reverse, 5’-CCTAAAGGAGACCACAGTTAGAG-3’; GAPDH forward, 5’-GGAAGATGGTGTAAGGATT-3’ and reverse, 5’-GGATTTGGTCGTATTGGG-3’. E-cadherin forward, 5’-GGCTGCGGCTGCAGACTGG-3’ and reverse, 5’-TACACTGGCCAGAGGCACA-3’; and vimentin forward, 5’-TGAATACCCGGAGACAGGTGCAG-3’ and reverse, 5’-GAGACCTGCTTCTCATAGTCAA-3’. The relative levels of gene expression were estimated by the 2⁻ΔΔCt method.

Western blot analysis. Total proteins were extracted from the cell lines using lysis buffer (Beyotime, Nantong, China) and phenylmethylsulfonyl fluoride (100:1). The concentrations of proteins were measured using a BCA kit (Beyotime). The proteins were then transferred to a nitrocellulose membrane using a semi-dry blotting apparatus (both from Bio-Rad, Hercules, CA, USA). The membrane was blocked in 5% skim milk diluted in Tris-buffered saline at room temperature for 2 h and then incubated with primary antibodies against anti-FOXQ1 (1:500), anti-BCL11A (1:800), anti-MDM2 (1:500), anti-E-cadherin (1:500), anti-vimentin (1:500) and anti-GAPDH (1:1,000) purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA) overnight at 4°C. The membrane was blotted with a horseradish peroxidase-conjugated secondary antibody (Cell Signaling Technology, Danvers, MA, USA; 1:1,000) for 2 h followed by washing with Tris-buffered saline with Tween (TBST). Finally, the target proteins were analyzed using a Bio-Rad ChemiDoc apparatus, and the signal intensity was measured by Image-Pro Plus 6.0 software.

Caspase-3 activity assay. Caspase-3 activity assay in the cells was assessed on the basis of the standard instructions of a Caspase-3 activity assay kit (Beyotime).

Annexin-V fluorescein isothiocyanate conjugate and propidium iodide Annexin V (Annexin V-FITC/PI). Apoptosis was assessed according to the manufacturer’s instructions in the Annexin V-FITC Apoptosis detection kit (Bender MedSystems, Vienna, Austria). The cells (5x10⁵ cells/ml) were resuspended in the binding buffer diluted in distilled deionized water (1:4) and mixed with 5 µl of Annexin V-FITC in 195 µl of the cell suspension. The mixture was then
incubated at room temperature for 10 min, then washed in phosphate-buffered saline. Thereafter, the cells were suspended in 190 µl of diluted binding buffer and 10 µl of PI was added. Apoptotic cells were counted using a FACS analyzer (Beckman Coulter, Brea, CA, USA).

**Measurement of cell growth and viability.** Cell growth and viability were tested using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The cells were plated in 96-well plates and cultured in an incubator with 5% CO₂ at 37°C. A total of 25 µl MTT (5 g/l) was added after removing the cell culture medium and allowed to react for 5 h at 37°C. Afterwards, the crystals were dissolved in 150 µl of dimethyl sulfoxide. The results were measured using an ELISA reader (Titertek Plus MS 212; ICN, Eschwege, Germany) at a wavelength of 490 nm. All experiments were performed in triplicate.

**Bromodeoxyuridine (BrDU) assay.** Cell proliferation was assessed by a BrDU cell proliferation assay kit (Millipore, Billerica, MA, USA). The protocols were performed as per the instructions. Cells were plated in 96-well plates and 10 µl of BrdU solution was added per well and allowed to react for 1 h. The culture medium was replaced by denaturing solution (100 µl/well) and incubated for 20 min. Thereafter, the detection antibody solution was added and incubated for 1.5 h at room temperature. The secondary antibody solution (100 µl/well) was added following three washes with wash buffer. Next, 100 µl tetramethylbenzidine (TMB) substrate was added and allowed to incubate for 25 min. The DNA incorporation of BrdU was detected at 450 nm on a Spectrofluor Plus Multiwell plate reader (Tecan, Research Triangle Park, NC, USA). All experiments were performed in triplicate.

**Cell invasion assay.** Prostate cancer cell invasion ability was detected using Bio-Coat cell migration chambers (BD Biosciences, San Jose, CA, USA). Filters (Corning Incorporated, Toledo, NY, USA) were coated with Matrigel (Becton Dickinson, Bedford, MA, USA). The cells were resuspended in 300 µl of serum-free medium (2x10⁵ cells) and added to the insert (top chamber). A total of 500 µl of culture medium with 10% FBS was then added to the lower chamber and cultured in an incubator with 5% CO₂ at 37°C. Non-invading cells were gently removed by a cotton swab, and invasive cells were fixed, stained and observed using a microscope. The number of invaded cells was counted in six random fields per membrane and averaged. Each assay was repeated three times.

**Construction of recombinant plasmids.** Full-length human BCL11A (NM_022893.3) was amplified using the reverse transcription polymerase chain reaction and then subcloned into the plasmid pcDNA.3.1/myc-His(-)Avector (Invitrogen, Carlsbad, CA, USA). The restriction sites of BCL11A cDNA and pcDNA.3.1/myc-His(-)Avector were EcoRI and BamHI. Next, the transformation of recombed plasmids into E. coli DH5α (Tiangen, Beijing, China) was conducted, and the recombed plasmids were amplified overnight at 37°C.

Figure 1. Relative mRNA expression of FOXQ1 in prostate cancer tissues. Relative mRNA expression of FOXQ1 was measured using RT-qPCR. GAPDH was used as the internal control. N, matched adjacent normal tissues; T, tumor tissues. n=10, *P<0.01 vs. the N group indicates a significant difference.

Finally, the amplified plasmids were extracted and sequenced, and designated as pcDNA.3.1/-BCL11A.

**Cell transfection.** The PC-3 (3x10⁴ cells/well) and DU-145 (3x10⁵ cells/well) cells were plated in 24-well plates, separately. Transfection of FOXQ1 small-interfering RNA (siRNA, 5'-CGCGGACTTTGCAGTTGA-3'), non-specific siRNA (5'-TTCTCCGAACGTCGACATTG-3') or co-transfection of pcDNA.3.1/-BCL11A and FOXQ1 siRNA was performed using Turbofect (Thermo Fisher Scientific) in accordance with the manufacturer's instructions. The transfected cells were maintained in an incubator (Thermo Fisher Scientific) with 5% CO₂ at 37°C for 48 h, and the transfection efficiency was measured by RT-qPCR and western blot analyses.

**Statistical analysis.** The statistical analyses were performed to test for statistically significant differences between two groups using Student's t-test and between multiple groups using one-way ANOVA. Data are expressed as the mean ± standard deviation (SD). A p-value of <0.05 was considered statistically significant.

**Results**

**High expression of FOXQ1 in prostate cancer tissues and cell lines.** To investigate the expression of FOXQ1 in prostate cancer, we tested the relative mRNA expression using RT-qPCR in tumor tissues and matched adjacent normal tissues. The data show that the mRNA expression of FOXQ1 was significantly higher in tumor tissue than in the matched adjacent normal tissues (Fig. 1). Furthermore, FOXQ1 mRNA and protein expression in prostate cancer cell lines, including PC-3, DU-145 and LNCaP, were measured by RT-qPCR and western blot analysis, respectively. The results show that the mRNA (Fig. 2A) and protein (Fig. 2B) expression of FOXQ1 in prostate cancer lines (PC-3, DU-145 and LNCaP) was obviously upregulated compared with the non-neoplastic cell line RWPE-1. These results indicate that FOXQ1 may play an important role in prostate cancer.

**FOXQ1 inhibition constrains the expression of BCL11A and MDM2.** To explore the influence of FOXQ1 on BCL11A and MDM2, we performed a FOXQ1 loss-of-function experiment in PC-3 and DU-145 cells by transfection with siRNA targeted to FOXQ1. The results show that the mRNA (Fig. 3A) and...
protein expression of FOXQ1 were both markedly decreased by FOXQ1 siRNA, as determined by RT-qPCR and western blot analysis, indicating that FOXQ1 inhibition was successful. Moreover, we found that FOXQ1 inhibition significantly decreased the protein expression of BCL11A and MDM2 (Fig. 3C) in prostate cancer cells.

**FOXQ1 inhibition induces prostate cancer cell apoptosis.** Next, we tested the effect of FOXQ1 inhibition on apoptosis in PC-3 and DU-145 cells using the Annexin V-FITC/PI assay and by assessing caspase-3 activity. In the Annexin V-FITC/PI assay, apoptosis was markedly increased by FOXQ1 siRNA (Fig. 4A). Furthermore, the results show that caspase-3 activity was
greatly increased by FOXQ1 inhibition (Fig. 4B). These results demonstrate that suppression of FOXQ1 promotes apoptosis in prostate cancer cells.

**Suppression of FOXQ1 inhibits prostate cancer cell proliferation and invasion.** To further investigate the biological effect of FOXQ1 inhibition in prostate cancer cells, we measured its effect on prostate cancer cell proliferation and invasion. The results show that prostate cancer cell proliferation was significantly restrained by FOXQ1 inhibition, as detected by the MTT (Fig. 5A) and BrdU (Fig. 5B) assays. Moreover, the Transwell invasion assay showed that FOXQ1 suppression significantly restrained the invasion ability of prostate cancer cells (Fig. 6A). Western blot analysis indicated that FOXQ1 suppression markedly increased E-cadherin expression and inhibited vimentin expression in prostate cancer cells (Fig. 6B). Above all, these results suggest that FOXQ1 inhibition suppresses the proliferation and invasion of prostate cancer cells.

**Inhibition of FOXQ1 constrains MDM2 by controlling BCL11A expression.** To investigate the potential molecular mechanism of FOXQ1 in prostate cancer, we performed co-transfection of FOXQ1 siRNA with the recombinant plasmid pcDNA.3.1/-BCL11A. The western blot analysis showed that upregulation of BCL11A significantly reversed the inhibitory effect of FOXQ1 siRNA on BCL11A expression (Fig. 7A and B). Furthermore, the decreased expression of MDM2 induced by FOXQ1 siRNA was also significantly reversed by BCL11A overexpression (Fig. 7A and B). Additionally, the induction of apoptosis (Fig. 8A) and inhibition of proliferation (Fig. 8B) and invasion (Fig. 8C) caused by FOXQ1 suppression were all obviously reversed by BCL11A overexpression.

**Discussion**

As a malignant tumor, the morbidity of prostate cancer is increasing and the therapy for this disease is still a challenge (37). In recent years, the FOXQ1 oncogene has attracted increasing attention in the cancer field. Studies have shown that FOXQ1 is a transcription factor that plays a role in cancer metastasis and development (38). It has been reported that high expression of FOXQ1 is found in cancers such as NSCLC, colorectal cancer, breast cancer, glioma, and hepatocellular carcinoma (39). FOXQ1 overexpression enhances invasion and metastasis by promoting EMT activity in bladder cancer and...
Figure 6. Effects of FOXQ1 suppression on invasion and EMT in prostate cancer cells. Invasion and EMT were assessed in prostate cancer cells using the Transwell invasion assay (A) and western blot analysis (B), respectively. *P<0.05 vs. the non-specific siRNA group.

Figure 7. Protein expression of genes in prostate cancer cell lines with co-transfection. The protein expression of FOXQ1, BCL11A and MDM2 were detected by western blot analysis in PC-3 (A) and DU-145 (B) cell lines. FOXQ1 siRNA-pcDNA.3.1, cells co-transfected with FOXQ1 siRNA and pcDNA.3.1/myc-His(-) Avector; FOXQ1 siRNA-pcDNA.3.1, cells co-transfected with FOXQ1 siRNA and pcDNA.3.1-BCL11A. **P<0.01 vs. the FOXQ1 siRNA-pcDNA.3.1 group.

Figure 8. Effects of co-transfection on apoptosis, proliferation and invasion in prostate cancer cell lines. Apoptosis (A), proliferation (B) and invasion (C) were measured using caspase-3 activity detection, the MTT assay and Transwell invasion assay, respectively. *P<0.05 and **P<0.01 vs. the FOXQ1 siRNA-pcDNA.3.1 group.
breast cancer, and FOXQ1 inhibition has an inhibitory effect on tumor growth and metastasis in bladder cancer and nasopharyngeal carcinoma (22,40,41). It has also been demonstrated that FOXQ1 overexpression indicates a poor prognosis in NSCLC (4). However, whether FOXQ1 plays an important role in prostate cancer remained unclear. In this study, we found that FOXQ1 is upregulated in tumor tissues and cell lines, and suppression of it can, in addition to constraining proliferation, invasion and EMT, induce apoptosis in prostate cancer cells. The foundation in our study is in line with previous studies in other cancers, further confirming its oncogenic function and providing a novel target in the prevention and therapy for this disease.

BCL11A is a transcription factor with a Krüppel zinc-finger motif, and the expression of BCL11A is required for not only the development pre-B-cells as well as thymocyte maturity, but also immunoglobulin switching (42-44). Moreover, BCL11A has been related to cancer. It is predicated that BCL11A has a positive role in cancers such as NSCLC, acute lymphoblastic leukemia, triple-negative breast cancer, squamous cell carcinoma as well as large cell carcinoma (45,46). Additionally, studies have shown that FOXQ1 has an effect on the expression of BCL11A in colorectal cancer (21). Thus, we speculated that FOXQ1 facilitates the expression of BCL11A in prostate cancer. As expected, inhibition of FOXQ1 had a significant repressive influence on BCL11A expression in our research. Furthermore, a recent study showed that BCL11A deficient B cells exhibit reduced expression of MDM2 (25). MDM2 exerts oncogenic functions in many cancers mainly via the inhibition of the tumor suppressor p53 (47). MDM2 gene mutation or abnormal expression leads to the destruction of the physiological balance, and is associated with cell transformation and tumorigenesis (48). Targeting the p53-MDM2 interaction has been considered as a method of treating cancer, includes the inhibition of MDM2 expression. PLoS One 8: e55693, 2013.

References

References


